| Caitlin Alise White, MD | |
|
3400 Civic Center Blvd, Pcam 4 W Pavillion, Philadelphia, PA 19104-5127 | |
| (215) 662-2300 | |
| Not Available |
| Full Name | Caitlin Alise White |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 14 Years |
| Location | 3400 Civic Center Blvd, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285952374 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD448860 (Pennsylvania) | Primary |
| 207R00000X | Internal Medicine | MD448860 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Penn Presbyterian Medical Center | Philadelphia, PA | Hospital |
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Pennsylvania Hospital | Philadelphia, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Penn - Medical Group | 6204730955 | 3031 |
News Archive
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
New research published in this month's Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.
Neurotransmitter transporters are some of the most popular transport proteins in research as they play a major role in the processing of signals in the brain. A joint study by TU Wien and the Medical University of Vienna has now successfully demonstrated for the first time the structural impact of membrane lipids on medically relevant serotonin transporters.
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
› Verified 5 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568579266 PECOS PAC ID: 6204730955 Enrollment ID: O20150204001537 |
News Archive
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
New research published in this month's Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.
Neurotransmitter transporters are some of the most popular transport proteins in research as they play a major role in the processing of signals in the brain. A joint study by TU Wien and the Medical University of Vienna has now successfully demonstrated for the first time the structural impact of membrane lipids on medically relevant serotonin transporters.
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
› Verified 5 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477658599 PECOS PAC ID: 6204730955 Enrollment ID: O20150205000131 |
News Archive
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
New research published in this month's Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.
Neurotransmitter transporters are some of the most popular transport proteins in research as they play a major role in the processing of signals in the brain. A joint study by TU Wien and the Medical University of Vienna has now successfully demonstrated for the first time the structural impact of membrane lipids on medically relevant serotonin transporters.
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Alise White, MD 3400 Civic Center Blvd, Pcam 4 W Pavillion, Philadelphia, PA 19104-5127 Ph: (215) 662-2300 | Caitlin Alise White, MD 3400 Civic Center Blvd, Pcam 4 W Pavillion, Philadelphia, PA 19104-5127 Ph: (215) 662-2300 |
News Archive
Altering the protein recycling complexes in human cells, including cancer cells, allows the cells to resist treatment with a class of drugs known as proteasome inhibitors, according to Whitehead Institute scientists.
New research published in this month's Rheumatology journal has found that having gout doubles the risk of heart attack and stroke. The research tracked the health of more than 205,000 gout patients using data spanning five decades to determine links between gout and heart attack and stroke.
Neurotransmitter transporters are some of the most popular transport proteins in research as they play a major role in the processing of signals in the brain. A joint study by TU Wien and the Medical University of Vienna has now successfully demonstrated for the first time the structural impact of membrane lipids on medically relevant serotonin transporters.
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
› Verified 5 days ago
Philippe Olivier Szapary, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |